Back to results

BIO14095-T1

Ox1R agonists for the treatment of autoimmunity diseases

TherapeuticApplication

Inflammatory Bowel Disease / Crohn's DiseaseTherapy Area

TargetType of patent

More information (PDF)

Keywords : -

Patent Application number : -

Patent Application date : 2014-06-24

Multidisciplinary field : -

Technology/Engineering : -

Technological Platform : -

Rare disease : -

Second indication : -

Inventors : Alain COUVINEAU
Nassima MESSAL
Eric OGIER-DENIS
Thierry VOISIN
Xavier TRETON

Publications : -

Print the offer Share

Business Developer
Contact

Sylvestre CHEA Business Development Manager

Phone number: +33 1 55 03 01 67 Email: c3lsdmVzdHJlLmNoZWFAaW5zZXJtLXRyYW5zZmVydC5mcg==

Back to results

Related offers

Gfi1 AS A NEW TARGET FOR THE TREATMENT OF HYPERGLYCEMIA AND DIABETES

Gfi1 is expressed in...

Gfi1 AS A NEW TARGET FOR THE TREATMENT OF HYPERGLYCEMIA AND DIABETES

Gfi1 is expressed in the pancreas, starting from the first stages of pancreatic embryonic development....

USE OF SHP2 INHIBITORS FOR THE TREATMENT OF INSULIN RESISTANCE

Despite reaching an epidemic...

USE OF SHP2 INHIBITORS FOR THE TREATMENT OF INSULIN RESISTANCE

Despite reaching an epidemic status worldwide, metabolic disorders, notably diabetes, still miss efficient and specific...

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE

The present invention relates...

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE

The present invention relates to methods and pharmaceutical compositions for the treatment of chronic kidney...

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CARDIAC REMODELING

The present invention relates...

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CARDIAC REMODELING

The present invention relates to the treatment of cardiac remodelling. In this study, the inventors...

USE OF PI3KC2¿ INHIBITORS FOR THE PRESERVATION OF VASCULAR ENDOTHELIAL CELL BARRIER INTEGRITY

Ischemic conditions are a...

USE OF PI3KC2¿ INHIBITORS FOR THE PRESERVATION OF VASCULAR ENDOTHELIAL CELL BARRIER INTEGRITY

Ischemic conditions are a leading cause of death for both men and women. Ischemia, a...

NEUTRALIZING GRANZYME B FOR PROVIDING CARDIOPROTECTION IN A SUBJECT WHO EXPERIENCED A MYOCARDIAL INFARCTION

The present invention relates...

NEUTRALIZING GRANZYME B FOR PROVIDING CARDIOPROTECTION IN A SUBJECT WHO EXPERIENCED A MYOCARDIAL INFARCTION

The present invention relates to a method for providing cardioprotection in a subject who experienced...

METHODS AND COMPOSITIONS FOR TREATING ASTHMA AND ALLERGIC DISEASES

The present invention relates...

METHODS AND COMPOSITIONS FOR TREATING ASTHMA AND ALLERGIC DISEASES

The present invention relates to allergy field. Several independent groups have recently investigated the implication...

Use of NGAL Inhibitors for treating chronic wound

Chronic wounds and in...

Use of NGAL Inhibitors for treating chronic wound

Chronic wounds and in particular diabetic ulcers are a serious complication of diabetes. Unresolved inflammation,...

Novel melanoma antigens

The invention relates to...

Novel melanoma antigens

The invention relates to melanoma antigen named MELOE and their use for preventing, treating and...

Anti-Cathepsin D human antibody for Triple Negative Breast Cancer Treatment

Inventors have generated two...

Anti-Cathepsin D human antibody for Triple Negative Breast Cancer Treatment

Inventors have generated two human anti-cath-D scFv fragments cloned in the human IgG1 format (F1...

Anti-Nectin-4 monoclonal antibodies

The present invention relates...

Anti-Nectin-4 monoclonal antibodies

The present invention relates to a new antibody anti-nectin-4. Nectin-4 is a tumor-associated antigen overexpressed...

A CLEC12B antagonist for treating hyperpigmentation disorders

The present invention relates...

A CLEC12B antagonist for treating hyperpigmentation disorders

The present invention relates to a method for treating hyperpigmentary skin disorder. By using normal...

‹ ›

The 10 Last viewed

You haven't seen any form yet.